Correlation of @entity876 status with outcome of neoadjuvant chemotherapy using @entity1311 and @entity632 in stage XXXX @entity0 .

@entity1 @entity632 @entity390 @entity0 @entity5 @entity72643 @entity1311 @entity876 @entity1431
BACKGROUND: The role of @entity876 in modulating apoptosis has suggested that it may affect efficacy of anticancer agents. We prospectively evaluated @entity876 alterations in 73 @entity1 with locally advanced @entity0 ( @entity72643 ) submitted to neoadjuvant chemotherapy. @entity1 AND METHODS: @entity1 received three cycles of @entity1311 (175 mg/m2) and @entity632 (60 mg/m2) every 21 days. @entity5 sections were analyzed before treatment for altered patterns of @entity876 expression using immunohistochemistry and DNA sequencing. RESULTS: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 @entity390 and 12.8% grade 3/4 @entity1431 . There was a statistically significant correlation between response and expression of @entity876 . Of the 25 @entity1 who obtained a complete clinical response, two were classified as positive (P = 0.004, chi-square). Of 11 @entity1 who obtained a complete pathological remission, one was positive (P = 0.099, chi-square). Discussion The combination is highly effective in locally advanced @entity0 . A negative expression of @entity876 indicates a higher chance of responding to this regimen. The @entity876 status may be used as a biological marker to identify those @entity1 who would benefit from more aggressive treatments.
